Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $155.44, marking a +0.18% move from the previous day.
The Zacks Analyst Blog Highlights JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP
by Zacks Equity Research
JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP are included in this Analyst Blog.
Top Stock Reports for JPMorgan, Abbott, Qualcomm & Others
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm, Inc. (QCOM).
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $155.06 in the latest trading session, marking a +0.41% move from the prior day.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
by Kinjel Shah
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
J&J (JNJ) Announces 2024 and Long-Term Financial Outlook
by Zacks Equity Research
J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks
by Zacks Equity Research
Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks are included in this Analyst Blog.
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $158.55, marking a -0.21% move from the previous day.
Top Analyst Reports for Johnson & Johnson, T-Mobile & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
by Zacks Equity Research
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.11, denoting a +0.32% change from the preceding trading day.
4 Large Drug Stocks to Watch as IBD Market Gains Traction
by Kinjel Shah
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VONV
Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More
by Kinjel Shah
Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.
The Zacks Analyst Blog Highlights Novo Nordisk Bank of America, Netflix, Johnson & Johnson and TotalEnergies
by Zacks Equity Research
Novo Nordisk, Bank of America, Netflix, Johnson & Johnson and TotalEnergies are part of the Zacks top Analyst Blog.